Current Opinion in Investigational Drugs 2004-09-01

ETC-588 (Pfizer).

Sheila A Doggrell

文献索引：Curr. Opin. Investig. Drugs 5(9) , 993-9, (2004)

摘要

Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete.

结构式	名称/CAS号	分子式	全部文献
	1-油酰基-2-棕榈酰基-sn-甘油-3-磷酸胆碱 CAS:59491-62-2	C₄₂H₈₂NO₈P

Barotropic and thermotropic bilayer phase behavior of positi...
2009-05-01
[Biochim. Biophys. Acta 1788(5) , 1056-63, (2009)]

Bridging the gap between molecular descriptors and mechanism...
2009-01-01
[J. Mol. Graph. Model. 27(7) , 829-35, (2009)]

The cytoplasmic region of mouse Fc gamma RIIb1, but not Fc g...
1999-02-16
[Biochemistry 38(7) , 2102-9, (1999)]

Immobilized liposome chromatography for studies of protein-m...
1998-08-07
[J. Chromatogr. B. Biomed. Sci. Appl. 712(1-2) , 59-71, (1998)]

Fourier transform infrared spectroscopy as a probe for the s...
1998-01-01
[Biospectroscopy 4(4) , 267-80, (1998)]

ETC-588 (Pfizer).

摘要

相关化合物